DONALD SCOTT MARKS
- Type
- Physician · Allopathic & Osteopathic Physicians / Psychiatry & Neurology / Neurology
- Where
- NANTUCKET, MA
- NPI
- 1982680740
- Received
- $94,088 in 121 records, 2019 to 2025 ($52,526 general, $41,562 research)
- As principal investigator
- $7,757,721 of research payments to others in 288 records
- Source
- CMS Open Payments search ↗
By year
| Program year | Kind | Records | Amount |
|---|---|---|---|
| 2025 | General payment | 5 | $678 |
| 2025 | Research payment | 6 | $32,769 |
| 2024 | General payment | 43 | $30,129 |
| 2024 | Research payment | 1 | $1,963 |
| 2023 | General payment | 19 | $12,363 |
| 2023 | Research payment | 1 | $300 |
| 2022 | General payment | 9 | $1,244 |
| 2022 | Research payment | 2 | $2,891 |
| 2021 | General payment | 4 | $6,467 |
| 2020 | General payment | 5 | $90 |
| 2020 | Research payment | 1 | $3,638 |
| 2019 | General payment | 25 | $1,553 |
By company
| Company | Records | Amount | Years |
|---|---|---|---|
| Eisai Inc. | 77 | $71,223 | 2019–2025 |
| Eli Lilly and Company | 5 | $8,792 | 2020–2024 |
| E.R. Squibb & Sons, L.L.C. | 4 | $7,416 | 2024–2025 |
| Biogen, Inc. | 10 | $4,948 | 2019–2025 |
| Alnylam Pharmaceuticals Inc. | 9 | $1,259 | 2024 |
| Genentech USA, Inc. | 4 | $162 | 2019–2021 |
| Lilly USA, LLC | 1 | $68 | 2023 |
| Novartis Pharmaceuticals Corporation | 2 | $46 | 2019–2020 |
| Life Molecular Imaging Ltd | 1 | $27 | 2025 |
| Adamas Pharmaceuticals, Inc. | 1 | $23 | 2019 |
| GENZYME CORPORATION | 1 | $21 | 2019 |
| Abbott Laboratories | 1 | $21 | 2025 |
| Boston Scientific Corporation | 1 | $20 | 2020 |
| Neuronetics, Inc. | 1 | $16 | 2020 |
| Teva Pharmaceuticals USA, Inc. | 1 | $15 | 2019 |
| Amneal Pharmaceuticals LLC | 1 | $12 | 2019 |
| Allergan, Inc. | 1 | $12 | 2020 |
By nature of payment
| Nature | Records | Amount |
|---|---|---|
| Research payment | 11 | $41,562 |
| Compensation for serving as faculty or as a speaker for a medical education program | 11 | $15,925 |
| Consulting Fee | 7 | $12,812 |
| Travel and Lodging | 31 | $10,473 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a v | 5 | $10,450 |
| Food and Beverage | 56 | $2,865 |
Records
| Date | Company | Amount | Nature | Form | Product | Study | Year |
|---|---|---|---|---|---|---|---|
| 2025-12-03 | Biogen, Inc. | $24 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-12-02 | Biogen, Inc. | $115 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-09-15 | Eisai Inc. | $2,473 | Research payment | Cash or cash equivalent | Leqembi Drug, Neurology | A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety | 2025 |
| 2025-08-11 | Eisai Inc. | $2,473 | Research payment | Cash or cash equivalent | Leqembi Drug, Neurology | A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety | 2025 |
| 2025-07-25 | E.R. Squibb & Sons, L.L.C. | $5,735 | Research payment | Cash or cash equivalent | A Randomized, Double-blind, Placebo-controlled, Global Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-9 | 2025 | |
| 2025-07-21 | Eisai Inc. | $2,473 | Research payment | Cash or cash equivalent | Leqembi Drug, Neurology | A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety | 2025 |
| 2025-07-21 | Eisai Inc. | $1,508 | Research payment | Cash or cash equivalent | Leqembi Drug, Neurology | A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety | 2025 |
| 2025-07-17 | Abbott Laboratories | $21 | Food and Beverage | In-kind items and services | INFINITY Device, Structural Heart | 2025 | |
| 2025-07-07 | Eisai Inc. | $18,104 | Research payment | Cash or cash equivalent | Leqembi Drug, Neurology | A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety | 2025 |
| 2025-04-23 | Eisai Inc. | $490 | Consulting Fee | Cash or cash equivalent | Leqembi Drug, Neurology | 2025 | |
| 2025-02-14 | Life Molecular Imaging Ltd | $27 | Food and Beverage | Cash or cash equivalent | NEURACEQ Drug, Diagnostic Tracer | 2025 | |
| 2024-10-31 | Biogen, Inc. | $65 | Food and Beverage | In-kind items and services | 2024 | ||
| 2024-09-26 | Eisai Inc. | $2,940 | Consulting Fee | Cash or cash equivalent | Leqembi Drug, Neurology | 2024 | |
| 2024-09-24 | Eli Lilly and Company | $1,963 | Research payment | Cash or cash equivalent | ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY OF DONANEMAB IN EARLY SYMPTOMATIC ALZHEIMERS DISEASE | 2024 | |
| 2024-07-29 | Biogen, Inc. | $33 | Food and Beverage | In-kind items and services | 2024 | ||
| 2024-06-13 | Eisai Inc. | $1,470 | Consulting Fee | Cash or cash equivalent | Leqembi Drug, Neurology | 2024 | |
| 2024-05-21 | Eisai Inc. | $980 | Compensation for serving as faculty or as a speaker for a medical education program | Cash or cash equivalent | Leqembi Drug, Neurology | 2024 | |
| 2024-05-09 | Alnylam Pharmaceuticals Inc. | $219 | Travel and Lodging | In-kind items and services | 2024 | ||
| 2024-05-09 | Alnylam Pharmaceuticals Inc. | $130 | Food and Beverage | In-kind items and services | 2024 | ||
| 2024-05-09 | Alnylam Pharmaceuticals Inc. | $100 | Travel and Lodging | In-kind items and services | 2024 | ||
| 2024-05-09 | Alnylam Pharmaceuticals Inc. | $100 | Travel and Lodging | In-kind items and services | 2024 | ||
| 2024-05-09 | Alnylam Pharmaceuticals Inc. | $48 | Food and Beverage | In-kind items and services | 2024 | ||
| 2024-05-09 | Alnylam Pharmaceuticals Inc. | $35 | Food and Beverage | In-kind items and services | 2024 | ||
| 2024-05-09 | Alnylam Pharmaceuticals Inc. | $24 | Food and Beverage | In-kind items and services | 2024 | ||
| 2024-05-09 | Alnylam Pharmaceuticals Inc. | $24 | Food and Beverage | In-kind items and services | 2024 | ||
| 2024-04-26 | Alnylam Pharmaceuticals Inc. | $575 | Travel and Lodging | In-kind items and services | 2024 | ||
| 2024-04-15 | Eisai Inc. | $1,470 | Consulting Fee | Cash or cash equivalent | Leqembi Drug, Neurology | 2024 | |
| 2024-03-29 | E.R. Squibb & Sons, L.L.C. | $1,044 | Travel and Lodging | In-kind items and services | 2024 | ||
| 2024-03-29 | E.R. Squibb & Sons, L.L.C. | $328 | Travel and Lodging | In-kind items and services | 2024 | ||
| 2024-03-29 | E.R. Squibb & Sons, L.L.C. | $308 | Food and Beverage | Cash or cash equivalent | 2024 | ||
| 2024-03-26 | Eisai Inc. | $1,470 | Compensation for serving as faculty or as a speaker for a medical education program | Cash or cash equivalent | Leqembi Drug, Neurology | 2024 | |
| 2024-03-26 | Eisai Inc. | $1,225 | Compensation for serving as faculty or as a speaker for a medical education program | Cash or cash equivalent | Leqembi Drug, Neurology | 2024 | |
| 2024-03-26 | Eisai Inc. | $1,128 | Travel and Lodging | Cash or cash equivalent | Leqembi Drug, Neurology | 2024 | |
| 2024-03-26 | Eisai Inc. | $84 | Food and Beverage | Cash or cash equivalent | Leqembi Drug, Neurology | 2024 | |
| 2024-02-21 | Eisai Inc. | $3,920 | Compensation for serving as faculty or as a speaker for a medical education program | Cash or cash equivalent | Leqembi Drug, Neurology | 2024 | |
| 2024-02-21 | Eisai Inc. | $1,225 | Compensation for serving as faculty or as a speaker for a medical education program | Cash or cash equivalent | Leqembi Drug, Neurology | 2024 | |
| 2024-02-21 | Eisai Inc. | $1,225 | Compensation for serving as faculty or as a speaker for a medical education program | Cash or cash equivalent | Leqembi Drug, Neurology | 2024 | |
| 2024-02-21 | Eisai Inc. | $653 | Travel and Lodging | Cash or cash equivalent | Leqembi Drug, Neurology | 2024 | |
| 2024-02-21 | Eisai Inc. | $490 | Compensation for serving as faculty or as a speaker for a medical education program | Cash or cash equivalent | Leqembi Drug, Neurology | 2024 | |
| 2024-02-21 | Eisai Inc. | $395 | Travel and Lodging | Cash or cash equivalent | Leqembi Drug, Neurology | 2024 | |
| 2024-02-21 | Eisai Inc. | $339 | Travel and Lodging | Cash or cash equivalent | Leqembi Drug, Neurology | 2024 | |
| 2024-02-21 | Eisai Inc. | $331 | Travel and Lodging | Cash or cash equivalent | Leqembi Drug, Neurology | 2024 | |
| 2024-02-21 | Eisai Inc. | $240 | Travel and Lodging | Cash or cash equivalent | Leqembi Drug, Neurology | 2024 | |
| 2024-02-21 | Eisai Inc. | $204 | Travel and Lodging | Cash or cash equivalent | Leqembi Drug, Neurology | 2024 | |
| 2024-02-21 | Eisai Inc. | $203 | Travel and Lodging | Cash or cash equivalent | Leqembi Drug, Neurology | 2024 | |
| 2024-02-21 | Eisai Inc. | $124 | Food and Beverage | Cash or cash equivalent | Leqembi Drug, Neurology | 2024 | |
| 2024-02-21 | Eisai Inc. | $29 | Food and Beverage | Cash or cash equivalent | Leqembi Drug, Neurology | 2024 | |
| 2024-02-21 | Eisai Inc. | $12 | Food and Beverage | In-kind items and services | Leqembi Drug, Neurology | 2024 | |
| 2024-02-21 | Eisai Inc. | $7 | Travel and Lodging | Cash or cash equivalent | Leqembi Drug, Neurology | 2024 | |
| 2024-02-16 | Eisai Inc. | $490 | Compensation for serving as faculty or as a speaker for a medical education program | Cash or cash equivalent | Leqembi Drug, Neurology | 2024 | |
| 2024-02-07 | Eisai Inc. | $2,940 | Compensation for serving as faculty or as a speaker for a medical education program | Cash or cash equivalent | Leqembi Drug, Neurology | 2024 | |
| 2024-02-07 | Eisai Inc. | $1,408 | Travel and Lodging | Cash or cash equivalent | Leqembi Drug, Neurology | 2024 | |
| 2024-02-07 | Eisai Inc. | $1,225 | Compensation for serving as faculty or as a speaker for a medical education program | Cash or cash equivalent | Leqembi Drug, Neurology | 2024 | |
| 2024-02-07 | Eisai Inc. | $121 | Food and Beverage | Cash or cash equivalent | Leqembi Drug, Neurology | 2024 | |
| 2024-01-24 | Eisai Inc. | $735 | Compensation for serving as faculty or as a speaker for a medical education program | Cash or cash equivalent | Leqembi Drug, Neurology | 2024 | |
| 2023-11-27 | Eisai Inc. | $1,225 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Leqembi Drug, Neurology | 2023 | |
| 2023-11-27 | Eisai Inc. | $490 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Leqembi Drug, Neurology | 2023 | |
| 2023-11-07 | Eisai Inc. | $1,225 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Leqembi Drug, Neurology | 2023 | |
| 2023-11-07 | Eisai Inc. | $490 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Leqembi Drug, Neurology | 2023 | |
| 2023-10-27 | Eisai Inc. | $48 | Food and Beverage | Cash or cash equivalent | 2023 | ||
| 2023-10-26 | Biogen, Inc. | $130 | Food and Beverage | In-kind items and services | 2023 | ||
| 2023-10-25 | Lilly USA, LLC | $68 | Food and Beverage | In-kind items and services | AMYVID Drug, Neuroscience | 2023 | |
| 2023-08-12 | Eisai Inc. | $50 | Food and Beverage | Cash or cash equivalent | Leqembi Drug, Neurology | 2023 | |
| 2023-08-12 | Eisai Inc. | $50 | Food and Beverage | Cash or cash equivalent | Leqembi Drug, Neurology | 2023 | |
| 2023-08-12 | Eisai Inc. | $12 | Food and Beverage | Cash or cash equivalent | Leqembi Drug, Neurology | 2023 | |
| 2023-08-12 | Eisai Inc. | $12 | Food and Beverage | Cash or cash equivalent | Leqembi Drug, Neurology | 2023 | |
| 2023-08-11 | Eisai Inc. | $7,020 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Leqembi Drug, Neurology | 2023 | |
| 2023-08-11 | Eisai Inc. | $506 | Travel and Lodging | Cash or cash equivalent | Leqembi Drug, Neurology | 2023 | |
| 2023-08-11 | Eisai Inc. | $331 | Travel and Lodging | Cash or cash equivalent | Leqembi Drug, Neurology | 2023 | |
| 2023-08-11 | Eisai Inc. | $204 | Travel and Lodging | Cash or cash equivalent | Leqembi Drug, Neurology | 2023 | |
| 2023-08-11 | Eisai Inc. | $183 | Travel and Lodging | Cash or cash equivalent | Leqembi Drug, Neurology | 2023 | |
| 2023-08-11 | Eisai Inc. | $125 | Food and Beverage | Cash or cash equivalent | Leqembi Drug, Neurology | 2023 | |
| 2023-08-11 | Eisai Inc. | $69 | Food and Beverage | Cash or cash equivalent | Leqembi Drug, Neurology | 2023 | |
| 2023-04-22 | Eisai Inc. | $121 | Food and Beverage | Cash or cash equivalent | Leqembi Drug, Neurology | 2023 | |
| 2023-01-31 | Eli Lilly and Company | $300 | Research payment | In-kind items and services | A STUDY OF DONANEMAB (LY3002813) IN PARTICIPANTS WITH EARLY ALZHEIMER'S DISEASE (TRAILBLAZER-ALZ 2) | 2023 | |
| 2022-10-25 | Eisai Inc. | $17 | Food and Beverage | Cash or cash equivalent | 2022 | ||
| 2022-04-29 | Eli Lilly and Company | $2,337 | Research payment | In-kind items and services | ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY OF LY3372689 IN EARLY SYMPTOMATIC ALZHEIMER'S DISEASE | 2022 | |
| 2022-04-29 | Eli Lilly and Company | $554 | Research payment | In-kind items and services | ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY OF DONANEMAB IN EARLY SYMPTOMATIC ALZHEIMERS DISEASE | 2022 | |
| 2022-03-28 | Eisai Inc. | $49 | Food and Beverage | Cash or cash equivalent | 2022 | ||
| 2022-03-28 | Eisai Inc. | $44 | Food and Beverage | Cash or cash equivalent | 2022 | ||
| 2022-03-28 | Eisai Inc. | $35 | Food and Beverage | Cash or cash equivalent | 2022 | ||
| 2022-03-28 | Eisai Inc. | $12 | Food and Beverage | Cash or cash equivalent | 2022 | ||
| 2022-03-28 | Eisai Inc. | $12 | Food and Beverage | Cash or cash equivalent | 2022 | ||
| 2022-03-27 | Eisai Inc. | $270 | Travel and Lodging | Cash or cash equivalent | 2022 | ||
| 2022-03-27 | Eisai Inc. | $258 | Travel and Lodging | Cash or cash equivalent | 2022 | ||
| 2022-03-24 | Eisai Inc. | $543 | Travel and Lodging | Cash or cash equivalent | 2022 | ||
| 2021-04-15 | Biogen, Inc. | $697 | Consulting Fee | Cash or cash equivalent | ADUHELM Biological, NEUROLOGY | 2021 | |
| 2021-03-06 | Eisai Inc. | $2,025 | Consulting Fee | Cash or cash equivalent | None Drug, None | 2021 | |
| 2021-03-03 | Genentech USA, Inc. | $25 | Food and Beverage | In-kind items and services | OCREVUS Biological, Immunology | 2021 | |
| 2021-02-24 | Biogen, Inc. | $3,720 | Consulting Fee | Cash or cash equivalent | ADUHELM Biological, NEUROLOGY | 2021 | |
| 2020-08-24 | Allergan, Inc. | $12 | Food and Beverage | In-kind items and services | UBRELVY Drug, NEUROSCIENCE | 2020 | |
| 2020-06-11 | Eli Lilly and Company | $3,638 | Research payment | In-kind items and services | ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY OF DONANEMAB IN EARLY SYMPTOMATIC ALZHEIMERS DISEASE | 2020 | |
| 2020-02-26 | Novartis Pharmaceuticals Corporation | $24 | Food and Beverage | In-kind items and services | MAYZENT Drug, NEUROSCIENCE | 2020 | |
| 2020-02-18 | Boston Scientific Corporation | $20 | Food and Beverage | In-kind items and services | GENERAL - PAIN MANAGEMENT Device, PAIN MANAGEMENT | 2020 | |
| 2020-02-05 | Genentech USA, Inc. | $16 | Food and Beverage | In-kind items and services | OCREVUS Biological, Immunology | 2020 | |
| 2020-01-07 | Neuronetics, Inc. | $16 | Food and Beverage | In-kind items and services | NEUROSTAR TMS THERAPY Device, NEUROSTAR TMS THERAPY | 2020 | |
| 2019-12-05 | Biogen, Inc. | $63 | Food and Beverage | Cash or cash equivalent | 2019 | ||
| 2019-09-10 | Genentech USA, Inc. | $22 | Food and Beverage | In-kind items and services | OCREVUS Biological, Immunology | 2019 | |
| 2019-07-17 | GENZYME CORPORATION | $21 | Food and Beverage | In-kind items and services | LEMTRADA Drug, MULTIPLE SCLEROSIS | 2019 | |
| 2019-05-14 | Novartis Pharmaceuticals Corporation | $22 | Food and Beverage | In-kind items and services | 2019 | ||
| 2019-05-13 | Genentech USA, Inc. | $98 | Food and Beverage | In-kind items and services | 2019 | ||
| 2019-05-06 | Biogen, Inc. | $67 | Food and Beverage | Cash or cash equivalent | 2019 | ||
| 2019-04-23 | Adamas Pharmaceuticals, Inc. | $23 | Food and Beverage | In-kind items and services | GOCOVRI Drug, PD | 2019 | |
| 2019-04-08 | Eisai Inc. | $518 | Travel and Lodging | Cash or cash equivalent | Drug | 2019 | |
| 2019-04-08 | Eisai Inc. | $203 | Travel and Lodging | Cash or cash equivalent | Drug | 2019 | |
| 2019-04-08 | Eisai Inc. | $108 | Food and Beverage | Cash or cash equivalent | Drug | 2019 | |
| 2019-04-08 | Eisai Inc. | $54 | Travel and Lodging | Cash or cash equivalent | Drug | 2019 | |
| 2019-04-08 | Eisai Inc. | $52 | Travel and Lodging | Cash or cash equivalent | Drug | 2019 | |
| 2019-04-08 | Eisai Inc. | $50 | Food and Beverage | Cash or cash equivalent | Drug | 2019 | |
| 2019-04-08 | Eisai Inc. | $50 | Food and Beverage | Cash or cash equivalent | Drug | 2019 | |
| 2019-04-08 | Eisai Inc. | $37 | Travel and Lodging | Cash or cash equivalent | Drug | 2019 | |
| 2019-04-08 | Eisai Inc. | $25 | Food and Beverage | Cash or cash equivalent | Drug | 2019 | |
| 2019-04-08 | Eisai Inc. | $22 | Travel and Lodging | Cash or cash equivalent | Drug | 2019 | |
| 2019-04-08 | Eisai Inc. | $20 | Food and Beverage | Cash or cash equivalent | Drug | 2019 | |
| 2019-04-08 | Eisai Inc. | $12 | Food and Beverage | Cash or cash equivalent | Drug | 2019 | |
| 2019-04-08 | Eisai Inc. | $12 | Food and Beverage | Cash or cash equivalent | Drug | 2019 | |
| 2019-04-08 | Eisai Inc. | $5 | Travel and Lodging | Cash or cash equivalent | Drug | 2019 | |
| 2019-04-08 | Eisai Inc. | $3 | Travel and Lodging | Cash or cash equivalent | Drug | 2019 | |
| 2019-03-20 | Teva Pharmaceuticals USA, Inc. | $15 | Food and Beverage | In-kind items and services | AJOVY Drug, Central Nervous System | 2019 | |
| 2019-02-26 | Biogen, Inc. | $30 | Food and Beverage | In-kind items and services | 2019 | ||
| 2019-01-28 | Amneal Pharmaceuticals LLC | $12 | Food and Beverage | In-kind items and services | RYTARY Drug, NEUROLOGY | 2019 |
Research payments naming this person as principal investigator
| Date | Company | Paid to | Amount | Study | Year |
|---|---|---|---|---|---|
| 2025-12-15 | Eisai Inc. | Headlands Research | $13,105 | A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety | 2025 |
| 2025-11-17 | Eisai Inc. | Headlands Research | $5,881 | A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety | 2025 |
| 2025-10-20 | Eisai Inc. | Headlands Research | $3,118 | A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety | 2025 |
| 2025-09-01 | Biogen, Inc. | Headlands Research | $8,269 | A Phase 3b/4 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Verify the Clinical Bene | 2025 |
| 2025-07-14 | Eli Lilly and Company | HEADLANDS EASTERN MA LLC | $3,920 | A STUDY OF DONANEMAB (LY3002813) COMPARED WITH ADUCANUMAB IN PARTICIPANTS WITH EARLY SYMPTOMATIC ALZHEIMER'S DISEASE (TR | 2025 |
| 2025-06-24 | Eli Lilly and Company | DONALD S MARKS MD PC | $188 | ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY OF DONANEMAB IN EARLY SYMPTOMATIC ALZHEIMERS DISEASE | 2025 |
| 2025-04-23 | Biogen, Inc. | Headlands Research | $5,939 | Phase 3b Open-Label, Multicenter, Safety Study of BIIB037 (aducanumab) in Subjects with Alzheimers disease Who Had Previ | 2025 |
| 2025-03-18 | Eisai Inc. | Headlands Research Eastern Ma | $30,965 | A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety | 2025 |
| 2025-03-11 | Eli Lilly and Company | HEADLANDS EASTERN MA LLC | $8,727 | ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY OF LY3372689 IN EARLY SYMPTOMATIC ALZHEIMER'S DISEASE | 2025 |
| 2025-02-25 | E.R. Squibb & Sons, L.L.C. | Donald S Marks, Md, PC | $3,925 | A Randomized, Double-blind, Placebo-controlled, Global Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-9 | 2025 |
| 2025-01-21 | E.R. Squibb & Sons, L.L.C. | Headlands Research Eastern Ma | $183,417 | A Randomized, Double-blind, Placebo-controlled, Global Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-9 | 2025 |
| 2025-01-09 | Eli Lilly and Company | DONALD S MARKS MD PC | $478 | ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY OF LY3372689 IN EARLY SYMPTOMATIC ALZHEIMER'S DISEASE | 2025 |
| 2024-11-18 | Eisai Inc. | Headlands Research | $7,421 | A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety | 2024 |
| 2024-09-20 | Eisai Inc. | Headlands Research | $13,968 | A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety | 2024 |
| 2024-08-20 | Eisai Inc. | Headlands Research | $2,473 | A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety | 2024 |
| 2024-07-22 | Eisai Inc. | Headlands Research | $4,947 | A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety | 2024 |
| 2024-07-15 | E.R. Squibb & Sons, L.L.C. | Headlands Research Eastern Ma | $28,438 | Phase 2 PoC in Early AD Patients - A Randomized, Double-blind, Placebo-controlled, Global Study to Evaluate the Efficacy | 2024 |
| 2024-07-02 | Eisai Inc. | Headlands Research | $12,246 | A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety | 2024 |
| 2024-06-25 | E.R. Squibb & Sons, L.L.C. | Donald S Marks, Md, PC | $4,346 | Phase 2 PoC in Early AD Patients - A Randomized, Double-blind, Placebo-controlled, Global Study to Evaluate the Efficacy | 2024 |
| 2024-04-22 | Eisai Inc. | Headlands Research | $116,826 | A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety | 2024 |
| 2024-04-08 | Eisai Inc. | Headlands Research | $194 | A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety | 2024 |
| 2024-01-31 | Eli Lilly and Company | DONALD S MARKS MD PC | $3,552 | ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY OF DONANEMAB IN EARLY SYMPTOMATIC ALZHEIMERS DISEASE | 2024 |
| 2024-01-12 | Eli Lilly and Company | HEADLANDS EASTERN MA LLC | $3,250 | A STUDY OF DONANEMAB (LY3002813) COMPARED WITH ADUCANUMAB IN PARTICIPANTS WITH EARLY SYMPTOMATIC ALZHEIMER'S DISEASE (TR | 2024 |
| 2024-01-09 | Eli Lilly and Company | DONALD S MARKS MD PC | $2,449 | ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY OF LY3372689 IN EARLY SYMPTOMATIC ALZHEIMER'S DISEASE | 2024 |
| 2024-01-09 | Biogen, Inc. | Headlands Research | $29,923 | Phase 3b Open-Label, Multicenter, Safety Study of BIIB037 (aducanumab) in Subjects with Alzheimers disease Who Had Previ | 2024 |
| 2024-01-09 | Eli Lilly and Company | HEADLANDS EASTERN MA LLC | $191,917 | ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY OF DONANEMAB IN EARLY SYMPTOMATIC ALZHEIMERS DISEASE | 2024 |
| 2024-01-02 | Eli Lilly and Company | HEADLANDS EASTERN MA LLC | $149,933 | ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY OF LY3372689 IN EARLY SYMPTOMATIC ALZHEIMER'S DISEASE | 2024 |
| 2023-10-18 | Eli Lilly and Company | HEADLANDS EASTERN MA LLC | $5 | ASSESSMENT OF SAFETY TOLERABILITY AND EFFICACY OF LY3372689 IN EARLY SYMPTOMATIC ALZHEIMER'S DISEASE | 2023 |
| 2023-08-18 | Eisai Inc. | DONALD S MARKS MD PC | $16,115 | A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety | 2023 |
| 2023-07-11 | Eli Lilly and Company | HEADLANDS EASTERN MA LLC | $450,873 | A STUDY OF DONANEMAB (LY3002813) IN PARTICIPANTS WITH EARLY ALZHEIMER'S DISEASE (TRAILBLAZER-ALZ 2) | 2023 |
| 2023-06-14 | Eli Lilly and Company | HEADLANDS EASTERN MA LLC | $85,848 | ASSESSMENT OF SAFETY TOLERABILITY AND EFFICACY OF LY3372689 IN EARLY SYMPTOMATIC ALZHEIMER'S DISEASE | 2023 |
| 2023-06-13 | Eisai Inc. | DONALD S MARKS MD PC | $58,499 | A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety | 2023 |
| 2023-06-07 | Eli Lilly and Company | HEADLANDS EASTERN MA LLC | $19,932 | A PHASE 3 OPEN-LABEL PARALLEL-GROUP 2-ARM STUDY TO INVESTIGATE AMYLOID PLAQUE CLEARANCE WITH DONANEMAB COMPARED WITH ADU | 2023 |
| 2023-04-17 | Eli Lilly and Company | DONALD S MARKS MD PC | $19,153 | A PHASE 3 OPEN-LABEL PARALLEL-GROUP 2-ARM STUDY TO INVESTIGATE AMYLOID PLAQUE CLEARANCE WITH DONANEMAB COMPARED WITH ADU | 2023 |
| 2023-04-05 | Eisai Inc. | DONALD S MARKS MD PC | $31,605 | A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety | 2023 |
| 2023-04-01 | Eisai Inc. | DONALD S MARKS MD PC | $5,200 | AHEAD 3-45 Study: A Placebo-Controlled, Double-Blind, Parallel-Treatment Arm, 216 Week Study With an Extension Phase to | 2023 |
| 2023-04-01 | Eisai Inc. | DONALD S MARKS MD PC | $17,970 | AHEAD 3-45 Study: A Placebo-Controlled, Double-Blind, Parallel-Treatment Arm, 216 Week Study With an Extension Phase to | 2023 |
| 2023-04-01 | Eisai Inc. | DONALD S MARKS MD PC | $11,905 | AHEAD 3-45 Study: A Placebo-Controlled, Double-Blind, Parallel-Treatment Arm, 216 Week Study With an Extension Phase to | 2023 |
| 2023-04-01 | Eisai Inc. | DONALD S MARKS MD PC | $9,950 | AHEAD 3-45 Study: A Placebo-Controlled, Double-Blind, Parallel-Treatment Arm, 216 Week Study With an Extension Phase to | 2023 |
| 2023-03-07 | Eisai Inc. | DONALD S MARKS MD PC | $8,695 | A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety | 2023 |
| 2023-03-01 | Eisai Inc. | DONALD S MARKS MD PC | $6,450 | AHEAD 3-45 Study: A Placebo-Controlled, Double-Blind, Parallel-Treatment Arm, 216 Week Study With an Extension Phase to | 2023 |
| 2023-02-20 | Eisai Inc. | DONALD S MARKS MD PC | $24,097 | A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety | 2023 |
| 2023-02-17 | Eisai Inc. | DONALD S MARKS MD PC | $72,889 | A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety | 2023 |
| 2023-02-01 | Eisai Inc. | DONALD S MARKS MD PC | $21,205 | AHEAD 3-45 Study: A Placebo-Controlled, Double-Blind, Parallel-Treatment Arm, 216 Week Study With an Extension Phase to | 2023 |
| 2023-01-26 | Eli Lilly and Company | DONALD S MARKS MD PC | $943 | A PHASE 3 OPEN-LABEL PARALLEL-GROUP 2-ARM STUDY TO INVESTIGATE AMYLOID PLAQUE CLEARANCE WITH DONANEMAB COMPARED WITH ADU | 2023 |
| 2023-01-26 | Eli Lilly and Company | DONALD S MARKS MD PC | $8,800 | A STUDY OF DONANEMAB (LY3002813) IN PARTICIPANTS WITH EARLY ALZHEIMER'S DISEASE (TRAILBLAZER-ALZ 2) | 2023 |
| 2023-01-20 | Eisai Inc. | DONALD S MARKS MD PC | $11,797 | A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety | 2023 |
| 2023-01-12 | Biogen, Inc. | DONALD S MARKS MD PC | $78,615 | A Phase 3b/4 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Verify the Clinical Bene | 2023 |
| 2023-01-12 | Biogen, Inc. | DONALD S MARKS MD PC | $109,488 | Phase 3b Open-Label, Multicenter, Safety Study of BIIB037 (aducanumab) in Subjects with Alzheimers disease Who Had Previ | 2023 |
| 2023-01-10 | Eli Lilly and Company | DONALD S MARKS MD PC | $3,884 | ASSESSMENT OF SAFETY TOLERABILITY AND EFFICACY OF LY3372689 IN EARLY SYMPTOMATIC ALZHEIMER'S DISEASE | 2023 |
| 2023-01-06 | Eisai Inc. | DONALD S MARKS MD PC | $46,296 | A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety | 2023 |
| 2023-01-03 | Eli Lilly and Company | DONALD S MARKS MD PC | $65,755 | ASSESSMENT OF SAFETY TOLERABILITY AND EFFICACY OF LY3372689 IN EARLY SYMPTOMATIC ALZHEIMER'S DISEASE | 2023 |
| 2023-01-03 | Eli Lilly and Company | DONALD S MARKS MD PC | $263,376 | A STUDY OF DONANEMAB (LY3002813) IN PARTICIPANTS WITH EARLY ALZHEIMER'S DISEASE (TRAILBLAZER-ALZ 2) | 2023 |
| 2023-01-01 | Eisai Inc. | DONALD S MARKS MD PC | $6,640 | AHEAD 3-45 Study: A Placebo-Controlled, Double-Blind, Parallel-Treatment Arm, 216 Week Study With an Extension Phase to | 2023 |
| 2023-01-01 | Eisai Inc. | DONALD S MARKS MD PC | $19,545 | AHEAD 3-45 Study: A Placebo-Controlled, Double-Blind, Parallel-Treatment Arm, 216 Week Study With an Extension Phase to | 2023 |
| 2022-11-22 | Eisai Inc. | DONALD S MARKS MD PC | $12,499 | A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety | 2022 |
| 2022-10-19 | Eisai Inc. | DONALD S MARKS MD PC | $23,901 | A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety | 2022 |
| 2022-10-18 | Biogen, Inc. | DONALD S MARKS MD PC | $12,486 | A Phase 3b/4 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Verify the Clinical Bene | 2022 |
| 2022-09-21 | Eisai Inc. | DONALD S MARKS MD PC | $29,254 | A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety | 2022 |
| 2022-09-21 | Eisai Inc. | DONALD S MARKS MD PC | $20,162 | A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety | 2022 |
| 2022-08-23 | Eisai Inc. | DONALD S MARKS MD PC | $26,488 | A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety | 2022 |
| 2022-07-21 | Eisai Inc. | DONALD S MARKS MD PC | $9,901 | A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety | 2022 |
| 2022-07-21 | Eisai Inc. | DONALD S MARKS MD PC | $10,485 | A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety | 2022 |
| 2022-06-20 | Eisai Inc. | DONALD S MARKS MD PC | $2,831 | A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety | 2022 |
| 2022-06-20 | Eisai Inc. | DONALD S MARKS MD PC | $11,187 | A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety | 2022 |
| 2022-06-07 | Eisai Inc. | DONALD S MARKS MD PC | $25,462 | A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety | 2022 |
| 2022-05-20 | Eisai Inc. | DONALD S MARKS MD PC | $13,516 | A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety | 2022 |
| 2022-05-09 | Eli Lilly and Company | DONALD S MARKS MD PC | $189,658 | ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY OF LY3372689 IN EARLY SYMPTOMATIC ALZHEIMER'S DISEASE | 2022 |
| 2022-04-20 | Eisai Inc. | DONALD S MARKS MD PC | $20,617 | A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety | 2022 |
| 2022-04-20 | Eisai Inc. | DONALD S MARKS MD PC | $9,839 | A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety | 2022 |
| 2022-03-21 | Eisai Inc. | DONALD S MARKS MD PC | $4,203 | A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety | 2022 |
| 2022-03-21 | Eisai Inc. | DONALD S MARKS MD PC | $17,903 | A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety | 2022 |
| 2022-02-21 | Eisai Inc. | DONALD S MARKS MD PC | $5,446 | A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety | 2022 |
| 2022-02-21 | Eisai Inc. | DONALD S MARKS MD PC | $11,314 | A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety | 2022 |
| 2022-02-08 | Eli Lilly and Company | DONALD S MARKS MD PC | $121,949 | A PHASE 3, OPEN-LABEL, PARALLEL-GROUP, 2-ARM STUDY TO INVESTIGATE AMYLOID PLAQUE CLEARANCE WITH DONANEMAB COMPARED WITH | 2022 |
| 2022-01-25 | Eisai Inc. | DONALD S MARKS MD PC | $14,239 | A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety | 2022 |
| 2022-01-21 | Biogen, Inc. | DONALD S MARKS MD PC | $4,502 | Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Safety, Tolerability, and Efficacy of B | 2022 |
| 2022-01-21 | Biogen, Inc. | DONALD S MARKS MD PC | $193,297 | Phase 3b Open-Label, Multicenter, Safety Study of BIIB037 (aducanumab) in Subjects with Alzheimer's disease Who Had Prev | 2022 |
| 2022-01-20 | Eli Lilly and Company | DONALD S MARKS MD PC | $7,327 | ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY OF DONANEMAB IN EARLY SYMPTOMATIC ALZHEIMERS DISEASE | 2022 |
| 2022-01-20 | Eisai Inc. | DONALD S MARKS MD PC | $13,869 | A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety | 2022 |
| 2022-01-13 | Eli Lilly and Company | DONALD S MARKS MD PC | $1,265 | A PHASE 3, OPEN-LABEL, PARALLEL-GROUP, 2-ARM STUDY TO INVESTIGATE AMYLOID PLAQUE CLEARANCE WITH DONANEMAB COMPARED WITH | 2022 |
| 2022-01-13 | Eli Lilly and Company | DONALD S MARKS MD PC | $20,895 | ASSESSMENT OF SAFETY, TOLERABILITY AND EFFICACY OF LY3002813 ALONE AND IN COMBINATION WITH LY3202626 IN EARLY SYMPTOMATI | 2022 |
| 2022-01-04 | Eli Lilly and Company | DONALD S MARKS MD PC | $5,401 | ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY OF LY3372689 IN EARLY SYMPTOMATIC ALZHEIMER'S DISEASE | 2022 |
| 2022-01-04 | Eli Lilly and Company | DONALD S MARKS MD PC | $882,115 | ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY OF DONANEMAB IN EARLY SYMPTOMATIC ALZHEIMERS DISEASE | 2022 |
| 2021-12-28 | Eli Lilly and Company | DONALD S MARKS MD PC | $99,610 | A PHASE 3, OPEN-LABEL, PARALLEL-GROUP, 2-ARM STUDY TO INVESTIGATE AMYLOID PLAQUE CLEARANCE WITH DONANEMAB COMPARED WITH | 2021 |
| 2021-12-20 | Eisai Inc. | DONALD S. MARKS, M.D., P.C. | $16,640 | A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety | 2021 |
| 2021-12-20 | Eisai Inc. | DONALD S. MARKS, M.D., P.C. | $32,130 | A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety | 2021 |
| 2021-12-01 | Eisai Inc. | DONALD S. MARKS, M.D., P.C. | $10,655 | A Study to Evaluate Efficacy and Safety of Treatment With Lecanemab in Participants With Preclinical Alzheimer's Disease | 2021 |
| 2021-12-01 | Eisai Inc. | DONALD S. MARKS, M.D., P.C. | $4,485 | A Study to Evaluate Efficacy and Safety of Treatment With Lecanemab in Participants With Preclinical Alzheimer's Disease | 2021 |
| 2021-11-19 | Eisai Inc. | DONALD S. MARKS, M.D., P.C. | $39,838 | A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety | 2021 |
| 2021-11-19 | Eisai Inc. | DONALD S. MARKS, M.D., P.C. | $3,421 | A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety | 2021 |
| 2021-11-05 | Eisai Inc. | DONALD S. MARKS, M.D., P.C. | $9,024 | A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety | 2021 |
| 2021-10-20 | Eisai Inc. | DONALD S. MARKS, M.D., P.C. | $3,519 | A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety | 2021 |
| 2021-10-20 | Eisai Inc. | DONALD S. MARKS, M.D., P.C. | $12,255 | A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety | 2021 |
| 2021-10-01 | Eisai Inc. | DONALD S. MARKS, M.D., P.C. | $3,770 | A Study to Evaluate Efficacy and Safety of Treatment With Lecanemab in Participants With Preclinical Alzheimer's Disease | 2021 |
| 2021-09-28 | Eli Lilly and Company | DONALD S MARKS MD PC | $787 | A PHASE 3, OPEN-LABEL, PARALLEL-GROUP, 2-ARM STUDY TO INVESTIGATE AMYLOID PLAQUE CLEARANCE WITH DONANEMAB COMPARED WITH | 2021 |
| 2021-09-24 | Eisai Inc. | DONALD S. MARKS, M.D., P.C. | $19,913 | A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety | 2021 |
| 2021-09-22 | Eisai Inc. | DONALD S. MARKS, M.D., P.C. | $6,146 | A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety | 2021 |
| 2021-08-20 | Eisai Inc. | DONALD S. MARKS, M.D., P.C. | $19,147 | A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety | 2021 |
| 2021-07-20 | Eisai Inc. | DONALD S. MARKS, M.D., P.C. | $51,128 | A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety | 2021 |
CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.
The area Census
County outline, the place (blue), the tract (orange) and the ZIP center (dot).
In Nantucket, MA, county Nantucket County, MA, state Massachusetts; placed by its city name.
| Measure | Place (city or town) Nantucket, MA | County Nantucket County, MA | State Massachusetts |
|---|---|---|---|
| Population B01003 | 10,017 | 14,483 | 7,044,056 |
| Population, 2020 census P1 | 10,166 | 14,255 | 7,029,917 |
| Median age B01002 | 42.2 | 42.4 | 40.0 |
| Under 18 B01001 | 18.4% | 20.5% | 19.4% |
| 65 and over B01001 | 16.1% | 16.1% | 17.9% |
| Households B11001 | 3,500 | 5,252 | 2,785,042 |
| Foreign born B05002 | 14.0% | 15.8% | 18.0% |
| Median household income B19013 | $148,017 | $139,688 | $103,960 |
| Median family income B19113 | $163,444 | $154,777 | $131,675 |
| Per capita income B19301 | $79,413 | $77,014 | $57,897 |
| Poverty rate B17001 | 3.2% | 3.2% | 10.0% |
| Unemployment rate B23025 | 6.1% | 4.3% | 5.2% |
| Civilian labor force B23025 | 6,040 | 8,574 | 3,911,446 |
| Mean commute (minutes) B08013 | 16.3 | 16.0 | 29.1 |
| Bachelor's degree or higher B15003 | 52.8% | 56.3% | 47.3% |
| Housing units B25001 | 6,805 | 12,594 | 3,030,406 |
| Owner-occupied B25003 | 80.8% | 71.8% | 62.5% |
| Renters B25003 | 19.2% | 28.2% | 37.5% |
| Median home value B25077 | $1,465,300 | $1,593,800 | $562,100 |
| Median gross rent B25064 | $2,228 | $2,213 | $1,762 |
| White, not Hispanic B03002 | 71.0% | 68.2% | 66.6% |
| Black B03002 | 6.7% | 9.4% | 6.4% |
| Hispanic or Latino B03002 | 16.9% | 17.0% | 13.3% |
| Asian B03002 | 0.6% | 1.7% | 7.3% |
| American Indian and Alaska Native B03002 | 0.1% | 0.1% | 0.1% |
Economy now FRED unemployment 4.3% in Sep 2026 (4.6% a year earlier); per capita personal income $98,700 in 2025, up 27% in five years (+2.3% after inflation); the state; Source: FRED, Federal Reserve Bank of St. Louis.
Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Nantucket, MA.
Comments